Related references
Note: Only part of the references are listed.Thiazolidinediones: effects on insulin resistance and the cardiovascular
C. E. Quinn et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Selective activation of peroxisome proliferator-activated receptor (PPAR)α and PPARγ induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism
Federico Biscetti et al.
DIABETES (2008)
Metabolic syndrome and cancer risk
Antonio Russo et al.
EUROPEAN JOURNAL OF CANCER (2008)
PPAR-γ ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo
I. K. Choi et al.
INVESTIGATIONAL NEW DRUGS (2008)
Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor γ
Yoshito Takeuchi et al.
CARCINOGENESIS (2007)
Delayed progression of pancreatic intraepithelial neoplasia in a conditional KrasG12D mouse model by a selective cyclooxygenase-2 inhibitor
Hitoshi Funahashi et al.
CANCER RESEARCH (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas
Edward Govannucci et al.
GASTROENTEROLOGY (2007)
The role of adjuvant chemotherapy for patients with resected pancreatic cancer: Systematic review of randomized controlled trials and meta-analysis
Stefan Boeck et al.
ONCOLOGY (2007)
Cancer statistics, 2007
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
Biology of PPAR gamma in cancer: A critical review on existing lacunae
Anand Krishnan et al.
CURRENT MOLECULAR MEDICINE (2007)
Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics?
ShouWei Han et al.
ANTI-CANCER DRUGS (2007)
Peroxisome proliferator-activated receptor γ is highly expressed in pancreatic cancer and is associated with shorter overall survival times
Glen Kristiansen et al.
CLINICAL CANCER RESEARCH (2006)
Epidemiology and risk factors for pancreatic cancer
AB Lowenfels et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2006)
3,3′-Diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5
M Abdelrahim et al.
CARCINOGENESIS (2006)
PPARγ and human metabolic disease
RK Semple et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Activation of peroxisome proliferator-activated receptor-γ decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system
H Sawai et al.
MOLECULAR CANCER RESEARCH (2006)
Peroxisome proliferator-activated receptor-gamma - Novel therapeutic target linking adiposity, insulin resistance, and atherosclerosis
Alper Kepez et al.
BIODRUGS (2006)
Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones
J-R Weng et al.
ENDOCRINE-RELATED CANCER (2006)
The potential of antidiabetic thiazolidinediones for anticancer therapy
Andrea Galli et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2006)
2-cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer
I Samudio et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Peroxisome proliferator-activated receptor γ agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/- double mutant mice
K Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key?
DL Feinstein et al.
BIOCHEMICAL PHARMACOLOGY (2005)
PPARs: therapeutic targets for metabolic disease
JP Berger et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2005)
Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells
Elisabetta Ceni et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
PPARs and the complex journey to obesity
RM Evans et al.
NATURE MEDICINE (2004)
PPARγ signaling exacerbates mammary gland tumor development
E Saez et al.
GENES & DEVELOPMENT (2004)
Activation and role of MAP kinases in 15d-PGJ2-induced apoptosis in the human pancreatic cancer cell line MIA PaCa-2
K Hashimoto et al.
PANCREAS (2004)
Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists
C Grommes et al.
LANCET ONCOLOGY (2004)
Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARγ independent mechanisms
A Galli et al.
GUT (2004)
COX and PPAR - Possible interactions in pancreatic cancer
G Eibl et al.
PANCREAS (2004)
Promotion of colon tumors in C57BL/6J-APC(min)/+ mice by thiazolidinedione PPAR gamma agonists and a structurally unrelated PPAR gamma agonist
MV Pino et al.
TOXICOLOGIC PATHOLOGY (2004)
Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells
W Motomura et al.
JOURNAL OF GASTROENTEROLOGY (2004)
Chemotherapy for pancreatic cancer
S Shore et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Therapeutic potential of thiazolidinediones as anticancer agents
D Panigrahy et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2003)
Cyclopentenone prostaglandin receptors
M Negishi et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2002)
Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone
S Kawa et al.
PANCREAS (2002)
Peroxisome proliferator-activated receptor γ induces pancreatic cancer cell apoptosis
G Eibl et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Share Paper
